Compass Minerals Engages in Major Debt Refinancing Following Insider Support
The company's price target was raised following the completion of $650 million senior notes offering.
A close up of an essential mineral being extracted from a large rock wall.
Headquartered in Kansas, Compass Minerals International, Inc. (NYSE:CMP) is a leading producer of essential minerals. Focusing on rock salt, sulfate of potash, and magnesium chloride, among others, the company serves deicing, agricultural, industrial, culinary, and consumer markets across North America and the U.K.
On June 3, 2025, Compass Minerals International, Inc. (NYSE:CMP) announced the pricing of a $650 million senior notes offering. Due in 2030, the notes carry an interest rate. And the proceeds from the notes are anticipated to be used for repaying debt while redeeming $350 million of senior notes due 2027. The offering was closed on June 16, 2025.
Following these developments, Deutsche Bank reiterated a Buy rating on the stock, while raising the price target from $14 to $22, signaling a high confidence in the company's progress.
From the insider's perspective as well, notable confidence is established on the stock, with Director Joseph Reece's purchase of 5000 shares on March 27, 2025, boosting the insider ownership by 0.05% in the last six months.
While we acknowledge the potential of CMP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: and 12 Best MLP Dividend Stocks to Buy According to Analysts
Disclosure. None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
How Abbott Laboratories (ABT) Balances Innovation with Shareholder Payouts
Abbott Laboratories (NYSE:ABT) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. An operating room with a doctor monitoring a patient's vital signs during surgery with a medical device. Abbott Laboratories (NYSE:ABT) has long held a strong position in the heavily regulated healthcare industry. Over the years, it has earned the trust of both doctors and consumers, making its well-established brands more appealing in the market. In recent years, Abbott Laboratories (NYSE:ABT)'s diabetes care division has emerged as its strongest growth engine, thanks largely to its continuous glucose monitoring (CGM) product line, FreeStyle Libre. According to the company, FreeStyle Libre has achieved record-breaking dollar sales, making it the most successful medical device in history. Despite this milestone, significant room for growth remains, as a large number of diabetics worldwide have yet to adopt CGM technology, despite its clear benefits. In addition, Abbott Laboratories (NYSE:ABT) holds the status of a Dividend King with 53 consecutive years of dividend growth under its belt. The company has grown its dividend payouts by nearly 146% over the past ten years. With a business model designed for durability, the company is seen as a reliable option for investors seeking steady dividend growth in the years ahead. It currently offers a quarterly dividend of $0.59 per share and has a dividend yield of 1.95%, as of July 17. While we acknowledge the potential of ABT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
24 minutes ago
- Yahoo
Is McKesson (MCK) an Overlooked Dividend Stock in the Pharma Sector for 2025?
McKesson Corporation (NYSE:MCK) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A successful pharmacist in front of shelves of drugs in a community-based oncology pharmacy. In its fourth-quarter 2025 earnings announcement, the company revealed plans to spin off its Medical-Surgical Solutions segment into a separate entity, referred to as 'NewCo.' Management emphasized that disciplined portfolio management remains a core element of its overall strategy. McKesson stated that this separation is expected to strengthen the strategic direction and operational focus of both businesses, while also delivering greater value to shareholders. McKesson Corporation (NYSE:MCK)'s cash position came in strong in fiscal 2025. Over the full fiscal year, the company returned $3.5 billion to its shareholders, comprising $3.1 billion in share buybacks and $345 million in dividends. It reported $6.1 billion in cash flow from operations and allocated $859 million toward capital expenditures, leading to a free cash flow of $5.2 billion. McKesson Corporation (NYSE:MCK) has been growing its payouts for eight consecutive years, and in the past five years, its dividend growth came in at nearly 12%. The company currently offers a quarterly dividend of $0.71 per share and has a dividend yield of 0.40%, as of July 17. While we acknowledge the potential of MCK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Associated Press
an hour ago
- Associated Press
Thomson Reuters Corp to Join the Nasdaq-100 Index® Beginning July 28, 2025
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Thomson Reuters Corp (Nasdaq: TRI), will become a component of the Nasdaq-100 Index® (Nasdaq: NDX®) and the Nasdaq-100 Equal Weighted™ Index (Nasdaq: NDXE™) prior to market open on Monday, July 28, 2025. Thomson Reuters Corp will replace ANSYS, Inc. (Nasdaq: ANSS) in the Nasdaq-100 Index® and the Nasdaq-100 Equal Weighted™ Index. ANSYS, Inc. will also be removed from the Nasdaq-100 Tech Sector™ Index (Nasdaq: NDXT™), the Nasdaq-100 Technology Sector Market-Cap Weighted™ Index (NDXTMC™), the Nasdaq-100 Technology Sector Adjusted Market-Cap Weighted™ Index (NDXT10™), the Nasdaq-100 ESG™ Index (Nasdaq: NDXESG™), the Nasdaq-100 ex Top 30™ Index (Nasdaq: NDX70™), the Nasdaq-100 ex Top 30 UCITS™ Index (Nasdaq: NDX70U™), and the Nasdaq-100 Select Equal Weight™ Index (NDXSE™) on the same date. Thomson Reuters Corp will replace ANSYS, Inc. in the Nasdaq-100 Tech Sector™ Index (Nasdaq: NDXT™), the Nasdaq-100 Technology Sector Market-Cap Weighted™ Index (NDXTMC™), and the Nasdaq-100 Technology Sector Adjusted Market-Cap Weighted™ Index (NDXT10™) on the same date. For more information about the company, go to About Nasdaq Nasdaq (Nasdaq: NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular financial product or an overall investment Inc. Media Contacts: Maximilian Leitenberger, Nasdaq, [email protected] Issuer & Investor Contact: Index Client Services, Nasdaq, [email protected] -NDAQG-
